Literature DB >> 16690200

The increased accumulation of structurally modified versican and decorin is related with the progression of laryngeal cancer.

S S Skandalis1, A D Theocharis, N Papageorgakopoulou, D H Vynios, D A Theocharis.   

Abstract

Versican and decorin, two proteoglycans (PGs) with contradictory roles in the pathophysiology of cancer, comprise important stromal components in many tumor types and play a crucial role in the progression of cancer. In this study, we provide direct evidence for a significant and stage-related accumulation of versican and decorin in the tumor-associated stroma of laryngeal squamous cell carcinoma (LSCC) in comparison to normal larynx. Both PGs were found to be co-localized within the peritumorous stroma. In addition, the accumulated versican and decorin were markedly modified on both protein core and glycosaminoglycan (GAG) levels. Decorin, which was present under both glycanated and non-glycanated forms, perceptibly increased with the progression of LSCC, compared to the normal larynx. Tumor-associated glycanated decorin was found to contain significant amounts of dermatan sulfate (DS) sequences. Versican was also found to undergo stage-related structural modifications since a marked heterogeneity of protein cores was observed, being intense in late stage of laryngeal cancer. The increased accumulation of both versican and decorin was associated with a significant stage-related increase of the molar ratio of Delta di-mono4S to Delta di-mono6S up to approximately threefold in LSCC compared to the normal ones. The modified chemical structure of both PGs could be associated with the degree of aggressiveness of laryngeal squamous cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16690200     DOI: 10.1016/j.biochi.2006.03.011

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  10 in total

1.  Altered expression of sialylated glycoproteins in breast cancer using hydrazide chemistry and mass spectrometry.

Authors:  Yuan Tian; Francisco J Esteva; Jin Song; Hui Zhang
Journal:  Mol Cell Proteomics       Date:  2012-02-07       Impact factor: 5.911

Review 2.  Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.

Authors:  Achilleas D Theocharis; Spyros S Skandalis; Thomas Neill; Hinke A B Multhaupt; Mario Hubo; Helena Frey; Sandeep Gopal; Angélica Gomes; Nikos Afratis; Hooi Ching Lim; John R Couchman; Jorge Filmus; Ralph D Sanderson; Liliana Schaefer; Renato V Iozzo; Nikos K Karamanos
Journal:  Biochim Biophys Acta       Date:  2015-03-28

Review 3.  Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer.

Authors:  Achilleas D Theocharis; Chrisostomi Gialeli; Panagiotis Bouris; Efstathia Giannopoulou; Spyros S Skandalis; Alexios J Aletras; Renato V Iozzo; Nikos K Karamanos
Journal:  FEBS J       Date:  2014-11-06       Impact factor: 5.542

4.  A role for versican in the development of leiomyosarcoma.

Authors:  Paul A Keire; Steven L Bressler; Joan M Lemire; Badreddin Edris; Brian P Rubin; Maziar Rahmani; Bruce M McManus; Matt van de Rijn; Thomas N Wight
Journal:  J Biol Chem       Date:  2014-10-15       Impact factor: 5.157

5.  Dermatan sulfate domains defined by the novel antibody GD3A12, in normal tissues and ovarian adenocarcinomas.

Authors:  Gerdy B Ten Dam; Shuhei Yamada; Fumi Kobayashi; Anurag Purushothaman; Els M A van de Westerlo; Johan Bulten; Anders Malmström; Kazuyuki Sugahara; Leon F Massuger; Toin H van Kuppevelt
Journal:  Histochem Cell Biol       Date:  2009-04-10       Impact factor: 4.304

6.  Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas.

Authors:  Spyros S Skandalis; Vassiliki T Labropoulou; Panagiota Ravazoula; Eleni Likaki-Karatza; Katalin Dobra; Haralabos P Kalofonos; Nikos K Karamanos; Achilleas D Theocharis
Journal:  BMC Cancer       Date:  2011-07-26       Impact factor: 4.430

7.  ADAMTS expression in colorectal cancer.

Authors:  Serafula Filou; Aggeliki Korpetinou; Dora Kyriakopoulou; Dimitrios Bounias; Michael Stavropoulos; Panagiota Ravazoula; Dionysios J Papachristou; Achilleas D Theocharis; Demitrios H Vynios
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

8.  Upregulation of Versican Associated with Tumor Progression, Metastasis, and Poor Prognosis in Bladder Carcinoma.

Authors:  Qi Zhang; Junxiu Wu; Xinpeng Chen; Ming Zhao; Dahong Zhang; Feng Gao
Journal:  Biomed Res Int       Date:  2021-02-02       Impact factor: 3.411

9.  Opticin, a small leucine-rich proteoglycan, is uniquely expressed and translocated to the nucleus of chronic lymphocytic leukemia cells.

Authors:  Eva Mikaelsson; Anders Osterborg; Zahra Tahmasebi Fard; Ahmad Mahmoudi; Jafar Mahmoudian; Mahmood Jeddi-Tehrani; Mehdi Akhondi; Fazel Shokri; Paul N Bishop; Hodjattallah Rabbani; Håkan Mellstedt
Journal:  Exp Hematol Oncol       Date:  2013-08-28

10.  An essential role for decorin in bladder cancer invasiveness.

Authors:  Mohamed El Behi; Sophie Krumeich; Catalina Lodillinsky; Aurélie Kamoun; Lorenzo Tibaldi; Gaël Sugano; Aurélien De Reynies; Elodie Chapeaublanc; Agnès Laplanche; Thierry Lebret; Yves Allory; François Radvanyi; Olivier Lantz; Ana María Eiján; Isabelle Bernard-Pierrot; Clotilde Théry
Journal:  EMBO Mol Med       Date:  2013-10-20       Impact factor: 12.137

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.